Apatite-Polymer Composite Particles for Controlled Delivery of BMP-2 by Yong, Tseh-Hwan et al.
  
  
Abstract — We have developed a versatile delivery 
platform comprising a novel composite of two 
biomaterials with proven track records: apatite and 
poly(lactic-co-glycolic acid) (PLGA).  These composites 
have been tested in the delivery of a model protein, 
bovine serum albumin (BSA), as well as a growth 
factor, bone morphogenetic protein-2 (BMP-2), which is 
a potent inducer of bone formation.  The controlled 
release strategy is based on the use of a polymer with 
acidic degradation products to control the dissolution of 
a basic inorganic component, resulting in protein 
release.  The release profile can be modified 
systematically by changing variables that affect 
polymer degradation and/or apatite dissolution, such as 
polymer molecular weight, polymer composition, 
apatite loading, and apatite particle size.  We have 
found that an increase in polymer molecular weight and 
polymer hydrophobicity led to slower polymer 
degradation, and in turn, slower apatite dissolution and 
protein release.  Protein release was enhanced by 
reducing apatite particle size and by lowering the 
apatite content in the composites.  We anticipate that 
this delivery platform can be extended to the controlled 
release of other therapeutic proteins and chemicals. 
 
 
Index Terms — Composite, apatite, PLGA, bone 
morphogenetic protein 
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I. INTRODUCTION 
one is a naturally regenerative tissue; it is able to heal 
from injury by recapitulating the embryonic skeletal 
developmental process.  However, an estimated 5-10% 
of fractures fail to recover properly and proceed to delayed 
union or nonunion [1].  The repair of bone loss associated 
with trauma and cancer is also typically not observed.  
Current treatment involves the implantation of autogenous 
or allogeneic bone grafts, a procedure that an estimated 
300,000 patients undergo in the United States each year [2].  
Autografts, long considered the gold standard in bone 
grafting, are plagued with problems of limited availability 
and morbidity associated with graft harvest.  The use of 
allografts is dampened by the risks of disease transfer and 
the costs of maintaining bone banks.  Synthetic grafts 
constructed of polymers, metals, and ceramics are also 
used, but their mechanical incompatibility with bone tissue 
often leads to implant failure.  The ideal solution would be 
to regenerate bone to fill the defects.  Bone morphogenetic 
proteins (BMPs), a group of potent growth factors 
belonging to the transforming growth factor-β (TGF-β) 
superfamily, have the ability to elicit new bone formation.  
These proteins provide a promising alternative to current 
bone grafts. 
 
 Among the osteoinductive BMPs, BMP-2, BMP-4 and 
BMP-7 appear to have greater potency [3,4] and are being 
produced with high bioactivity and purity via recombinant 
DNA technology.  BMP-2 and BMP-7 are currently in 
clinical use.   In vitro administration of BMP-2 and BMP-7 
to embryonic rat calvarial cells, rat osteosarcoma cells, or 
mouse fibroblasts resulted in enhanced osteogenic activity, 
as evidenced by differentiation into osteoblasts and 
elevated expression of bone mineralization proteins.  In 
vivo treatment with BMP-2 or BMP-7 augmented the 
healing of defects in rodents [5,6], rabbits [7-11], dogs [12-
14], sheep [15], and non-human primates [9,16,17].  
Critical-size defects, which do not heal spontaneously, were 
bridged within 3 months in primates [16,17].  These animal 
studies validate the safety and efficacy of BMP-2 and 
BMP-7 in promoting orthopedic repair.  However, the 
results from human trials have shown more variation.  
Geesink et al. reported that amongst six patients receiving 
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BMP-7 with a collagen carrier for the treatment of high 
tibial osteotomy, four showed bridging by 6 weeks, one by 
10 weeks, and one showed no bone formation during the 
course of the study [18].  When similar BMP-7 carriers 
were implanted in the maxillary sinuses of three patients 
with maxillary atrophy, only one exhibited satisfactory 
bone formation whereas the remaining two showed little 
bone formation after 6 months [3].  This suboptimal 
response in humans may be attributed to a smaller 
population of multipotent cells that are also less responsive 
than those in small animals.   
 
 To improve the efficacy of BMP treatment in higher 
mammals, optimal delivery of the therapeutic protein is 
crucial.  The objective of our research is to develop carriers 
that can retain and meter out BMPs at the appropriate dose 
and for a sufficient duration to allow the recruitment, 
migration, differentiation, and proliferation of bone-
forming cells.  In addition to sustained release, we seek to 
reduce burst release to avoid the adverse effects of an 
overdose and to conserve the protein, making the 
formulation more cost-effective.   
 
 In this paper, we describe a controlled delivery system 
for BMP-2 constructed from composites of apatite and 
poly(lactic-co-glycolic acid) (PLGA).  The controlled 
release strategy is based on the use of a polymer with acidic 
degradation products to control the dissolution of a basic 
inorganic component (apatite) on which a therapeutic agent 
(BMP-2) has been adsorbed.  The dissolution of the 
inorganic substrate results in the release of the therapeutic 
agent.  This strategy allows the systematic modulation of 
the release profile by changing variables that affect polymer 
degradation and/or apatite dissolution.  These variables 
include polymer type, polymer molecular weight, polymer 
composition (including copolymers and blends), apatite 
loading, and apatite particle size.  Controlled release of a 
model protein, bovine serum albumin (BSA), was first 
established, and then extended to BMP-2.   
 
II. EXPERIMENTAL 
A. Synthesis of Hydroxyapatite and Carbonated Apatite 
 Hydroxyapatite (HAP) and carbonated apatite (CAP)  
were synthesized according to the method developed by 
Ahn et al. [19-21].  For the synthesis of HAP, 900 ml of 
0.167 M Ca(NO3)2 (Fluka) and 900 ml of 0.100 M 
(NH4)2HPO4 (Fluka) were prepared in distilled water.  The 
pH of the (NH4)2HPO4 solution was raised to 10.4 with 
ammonium hydroxide.  The Ca(NO3)2 solution was added 
to the (NH4)2HPO4 solution at a rate of ~ 3 ml/min.  The 
resulting suspension was stirred at room temperature for 72 
h.  After this aging step, the white precipitate was collected 
by centrifugation, washed with aqueous NH4OH solutions 
of decreasing pH, followed by two ethanol washes.  The gel 
was air-dried overnight, then oven-dried at 120°C for 24 h.  
The dried gel was ground in a heated mortar and calcined at 
550°C for 2 h (ramp rate of 10°C/min).  After calcination, 
the HAP powder was sieved through a 45-µm mesh.  
 
 CAP was synthesized by the same method but with the 
following modifications.  (NH4)HCO3, the carbonate 
source, was added to the (NH4)2HPO4 solution to a 
concentration of 0.100 M.  After the oven-drying step, the 
gel was ground and sieved.  The powder was not calcined 
to avoid driving off the carbonate groups at elevated 
temperatures. 
 
 For the synthesis of submicron-sized apatite particles, 
modifications were made to the above protocol to reduce 
agglomeration.  Tween 80 (Aldrich) was added as a 
surfactant to constitute 10 v/v% of the (NH4)2HPO4/ 
(NH4)HCO3 solution.  Apatite was collected and washed by 
ultrafiltration instead of centrifugation.  The washed apatite 
was dried by lyophilization, which produced a fine, fluffy 
powder without the need for grinding or sieving.  
Calcination, which leads to grain growth, was not 
performed on these apatite powders.  The hydroxyapatite 
and carbonated apatite thus prepared are referred to as 
sHAP and sCAP, respectively. 
B. Characterization of Apatite 
Powder X-ray diffraction (XRD) patterns of the various 
apatite powders were obtained with a Siemens D5000 θ-
θ diffractometer (45 kV, 40 mA, Cu Kα).  Grain size 
analyses were performed on the <002> diffraction peaks 
using Scherrer’s method.  The BET surface areas of the 
apatite powders were determined by nitrogen adsorption on 
a Micromeritics ASAP 2000/2010 Analyzer.  Particle size 
distribution was evaluated using a Horiba CAPA-300 
Particle Size Analyzer. 
C. Preparation of Apatite-Protein Complexes 
Fluorescein isothiocyanate-bovine serum albumin (FITC-
BSA, Sigma), was used as a model protein.  FITC-BSA 
was dissolved in distilled water and added to an aqueous 
suspension of HAP, sHAP, CAP, or sCAP.  The suspension 
was stirred at room temperature for 16 h to allow the 
adsorption of the protein onto the apatite.  The BSA-apatite 
complex was collected by centrifugation, washed with 
distilled water, and lyophilized.  BMP-2 (R&D Systems) 
was adsorbed onto apatite by the same procedure, except 
the adsorption time was reduced to 8 h.  The amount of 
protein adsorbed was determined by measuring the protein 
concentrations of the initial stock solution and the 
supernatant after adsorption, and taking the difference.  
FITC-BSA concentration was analyzed by Coomassie Plus 
total protein assay (Pierce).  BMP-2 concentration was 
evaluated with an enzyme-linked immunosorbent assay 
(ELISA) kit (R&D Systems). 
D. Preparation of Composite Microparticles 
Composite microparticles were synthesized by a 
modification of a solid-in-oil-in-water emulsion process 
  
previously used to encapsulate proteins in the solid state 
[22].  A typical synthesis involves dissolving 250 mg of 
PLGA (24 kd, Alkermes) in 2 ml of dichloromethane.  To 
this polymer solution, 10 mg of protein-apatite complex 
was added and vortexed to create a uniform suspension.  
The solid-in-oil suspension was homogenized in 50 ml of 
0.1 w/v% aqueous methyl cellulose solution at 8000 rpm 
for 2 min at room temperature.  The resulting solid-in-oil-
in-water suspension was heated at 30°C for 3 h to drive off 
dichloromethane and solidify the particles.  The particles 
were collected by centrifugation, washed with distilled 
water, and lyophilized.  This protocol was systemically 
varied one parameter at a time to investigate the effect of 
different processing parameters.   
E.  Characterization of Microparticle Morphology and 
Size 
The morphology of the composite particles was 
evaluated by environmental scanning electron microscopy 
(ESEM, FEI/Philips XL30 FEG) at 6-7 kV.  The average 
particle size and size distribution were determined by 
measuring the dimensions of a minimum of 100 particles 
under ESEM. 
F.  Evaluation of In Vitro Release 
Thirty mg of protein-loaded composite microparticles 
were re-suspended in 1.5 ml of pH 7.4 N,N-bis(2-
hydroxyethyl)-2-aminoethanesulfonic acid (BES) buffer 
supplemented with 0.02 w/v% sodium azide.  The samples 
were incubated at 37°C.  At pre-determined time intervals 
(1, 4, 7, 14, 21, 28, 42, 56… days, up to 20 weeks), the 
samples were centrifuged, 0.75 ml of the supernatant was 
withdrawn and replaced with 0.75 ml of fresh BES buffer.  
For samples containing FITC-BSA, the collected 
supernatant was filtered and assayed for fluorescence, and 
stored at 4°C until further analysis of protein concentration 
with the Coomassie Plus total protein assay.  For samples 
containing BMP-2, the collected supernatant was filtered 
and stored at -20°C until evaluation by a BMP-2 ELISA 
kit.  The protein concentration at each time point was used 
to construct the cumulative release profiles. 
 
III. RESULTS AND DISCUSSION 
A. Characterization of Apatite 
 HAP and CAP had approximately the same particle size.  
The calcination step in the preparation of HAP led to grain 
growth and lower surface area (Table 1).  The use of 
surfactant in the synthesis of sHAP and sCAP contributed 
to less agglomeration and smaller particle size.  The 
particle sizes of sHAP and sCAP were 1.0 µm and 0.7 µm, 
respectively. 
 
 The higher the surface area, the greater the capacity is 
for protein adsorption.  However, the availability of surface 
area for adsorption is constrained by the pore size of the 
material.  Although the surface area of CAP was 3.5 times 
higher than that of HAP, the amount of BSA adsorbed was 
only 2.4 times higher.  The mean pore size of CAP was 8.2 
nm, which was equivalent to the hydrodynamic diameter of 
a BSA molecule.  Therefore, pores at the smaller end of the 
distribution were inaccessible to BSA.  Even in larger 
pores, the adsorption of one BSA molecule could have 
blocked off passage to the rest of the pore.   
 
TABLE 1 
PROPERTIES OF APATITE PREPARED WITH AND WITHOUT SURFACTANT 
Property CAP HAP 
Particle Size (µm) 6.8 5.3 
Grain Size (nm) 11.6 22.9 
Surface Area (m2/g) 302 86 
Pore Volume (cm3/g) 1.24 0.52 
Mean Pore Radius (nm) 8.2 12.2 
Maximum BSA Adsorption (wt%) 31.4 15.9 
 
B. Effect of Processing Parameters on Composite 
Particle Size 
ESEM micrographs of two representative sets of 
composite microparticles are shown in Fig. 1.  Both sets of 
particles have an average diameter of ~ 40 µm.  Particles 
prepared from submicron-sized sCAP have smoother 
surfaces whereas particles containing micron-sized CAP 
appear rougher and more porous. 
 
 
 
 
 
 
Fig. 1. ESEM micrographs of composite microparticles 
prepared from (a) sCAP and (b) CAP. 
(a) 
(b) 
  
 The effect of various processing parameters on the size 
of the composite particles is summarized in Table 2.  For 
each parameter, low and high values around a midpoint 
were investigated to obtain a sense of the general trend.  
Variations that caused higher shear during homogenization 
led to the creation of smaller particles.  For example, 
increase in homogenization speed and homogenization time 
directly increased the amount of shear experienced by the 
suspension.  Decrease in polymer solution concentration 
and polymer molecular weight reduced the viscosity of the 
organic phase and also reduced particle size concomitantly. 
 
TABLE  2 
EFFECT OF PROCESSING PARAMETERS ON COMPOSITE PARTICLE SIZE 
Processing Parameters Particle 
Size (µm) 
Standard processing conditions as described in 
Section II.D 
41 ± 12 
Increase homogenization speed to 12000 rpm 30 ± 8 
Increase homogenization speed to 16000 rpm 27 ± 8 
Decrease homogenization time to 1 min 55 ± 21 
Increase homogenization time to 4 min 31 ± 10 
Increase CH2Cl2 volume to 4 ml 27 ± 8 
Decrease in CH2Cl2 volume to 1 ml 65 ± 24 
Reduce aqueous surfactant volume to 25 ml 35 ± 12 
Increase aqueous surfactant volume to 100 ml 51 ± 15 
Increase CAP-BSA complex loading to 30 mg 37 ± 13 
Increase CAP-BSA complex loading to 50 mg 37 ± 12 
Decrease apatite particle size to 1 µm (use of 
sCAP) 
44 ± 13 
Use of lower molecular weight PLGA (6 kd) 23 ± 7 
Use of higher molecular weight PLGA (59 kd)  45 ± 15 
Blending in 20 wt% PLA (15-25 kd) 42 ± 13 
Blending in 60 wt% PLA (15-25 kd) 44 ± 12 
Blending in 10 wt% PEG (3.4 kd) 37 ± 12 
Blending in 30 wt% PEG (3.4 kd) 23 ± 7 
 
C. Effect of Processing Parameters on the In Vitro 
Release from Composite Microparticles 
1) Polymer Molecular Weight  
The molecular weight of a biodegradable polymer 
influences its degradation rate and lifetime.  As molecular 
weight increases, degradation becomes slower and 
longevity is extended.  Apatite-polymer composite particles 
were prepared from PLGA of different molecular weights 
ranging from 6 kd to 59 kd.  The onset of the accelerated 
phase of protein release was observed to occur at different 
times depending on the molecular weight of the polymer 
used (Fig. 2a).  For particles fabricated from the short-
chained, 6 kd and 13 kd PLGA, the rapid release phase 
began immediately.  An upturn in the release profile was 
seen at ~ 4 weeks for 24 kd PLGA, whereas release 
remained gradual up to 8 weeks for 59 kd PLGA.  Such 
control of release rate by polymer molecular weight may be 
useful in sequential release, such as to direct the debut of a 
protein in a wound healing process.  Polymers of different 
molecular weights could also be blended together to 
equalize the production of acid over time.  Through the use 
of an equi-proportion blend of 6, 13, 24, 59 and 75 kd 
PLGA, a sustained and gradual release of BMP-2 was 
obtained (Fig. 2b). 
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Fig. 2. Effect of PLGA molecular weight on protein release.  
(a) Particles contained 15 µg of FITC-BSA per mg carrier.  
(b) Particles contained 64.5 ng of BMP-2 per mg carrier. 
 
A comparison of Figs. 2a and 2b also reveals that the 
release profiles of BSA and BMP-2 from these composites 
are very similar, suggesting the same release mechanism for 
both proteins. 
 
2) Polymer Hydrophobicity 
Blends of PLGA and PLA 
 Composite particles were synthesized from blends of 
PLGA (50:50 copolymer) and poly(lactic acid) (PLA).  As 
the proportion of PLA in the composite particles was 
increased, the release rate decreased (Fig. 3).  Lactic acid 
(LA) contains a methyl group that augments its 
hydrophobicity relative to glycolic acid (GA).  Hence, PLA 
is more hydrophobic than PLGA.  An increase in polymer 
(b) 
(a) 
  
hydrophobicity would delay water penetration and polymer 
degradation, and consequently, reduce protein release from 
composite particles.  This parameter could be adjusted by 
using different types, blends, or compositions of polymers.  
For example, the LA to GA ratio in PLGA could be varied 
to obtain a range of hydrophobicities and degradation rates. 
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Fig. 3. Effect of polymer hydrophobicity on protein release.  
Particles contained 15 µg of FITC-BSA per mg carrier.  
Molecular weight of PLGA was 24 kd; molecular weight of 
PLA was 20-30 kd. 
Blends of PLGA and a Hydrophilic Polymer 
 Polyethylene glycol (PEG), a hydrophilic, 
biocompatible, and non-degradable polymer, was blended 
with PLGA in the fabrication of composite particles.  
Increase in PEG content led to faster initial release (Fig. 4).  
All release profiles showed an upturn at approximately 21 
days, which corresponded to the degradation of 24 kd 
PLGA.   
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Fig. 4. Effect of incorporating a hydrophilic polymer (PEG, 
3.4 kd) on protein release.  Particles contained 9 µg of 
FITC-BSA per mg carrier.  Molecular weight of PLGA was 
24 kd. 
  
 The hydrophilicity of PEG would draw water into the 
particles where the PEG chains reside.  In addition, PEG 
might leach out of the polymer matrix, leaving behind pores 
[23].  The aqueous channels thus formed would facilitate 
water penetration and PLGA hydrolysis, as well as protein 
diffusion out of the particles.  Therefore, the incorporation 
of a hydrophilic polymer would be expected to increase the 
rate of release. 
 
3) Apatite Particle Size 
 CAP-BSA complexes prepared from sCAP (1 µm) and 
CAP (7 µm) were incorporated into composite particles.  
Reducing the apatite particle size resulted in release that 
more closely approximated zero-order for a longer period 
of time (Fig. 5).  In contrast, the release plateaued after the 
first week of release from composite particles containing 
the larger, 7 µm-sized CAP particles.   
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Fig. 5. Effect of apatite particle size on protein release.  
Particles were fabricated from 59 kd PLGA and contained 
18 µg of FITC-BSA per mg of carrier. 
 
 For a given amount of acid produced by polymer 
degradation, a certain amount of apatite would be 
dissolved.  Consequently, the protein adsorbed on that 
amount of apatite would be released.  For small apatite 
particles, we surmise that most of the area available for 
protein adsorption is on the surface of the particles due to 
their higher surface/volume ratio, and their lower porosity 
and pore size compared to larger particles.  (sCAP has 
porosity of 0.27 cm3/g and mean pore size of 4.2 nm 
compared to porosity of 1.24 cm3/g and mean pore size of 
8.2 nm for CAP.) As the surface of the apatite particles is 
gradually eroded by acid dissolution, the protein is 
released.  For larger, porous apatite particles, the protein 
may be adsorbed on the surface as well as within the pores 
inside the particles.  To free the protein adsorbed within the 
pores, a larger volume of apatite has to be dissolved.  This 
difference in adsorption site may account for the difference 
in the release profiles for the 1 µm- and 7 µm-sized apatite 
particles.   
 
 
  
4) Addition of Buffering Apatite 
 In addition to apatite-protein complexes, we loaded 
varying amounts of bare apatite with no adsorbed protein, 
referred to as “buffering apatite”, into the composite 
particles.  As the proportion of buffering apatite was raised, 
the release rate decreased (Fig. 6).  Protein release was 
dependent on the dissolution of apatite by acidic polymer 
degradation products.  By incorporating buffering apatite 
into the composite particles, a portion of the acidity was 
neutralized by this bare apatite instead of by apatite-protein 
complexes.  As a result, less protein was released for each 
unit of acid produced.   
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Fig. 6. Effect of buffering apatite on protein release.  
Particles were fabricated from 24 kd PLGA and contained 
(♦) 9, () 8.4 and () 7.6 µg of FITC-BSA per mg of 
carrier. 
 
 
 5) Apatite-BSA Complex Loading in Particles 
 Different amounts of CAP-BSA with the same BSA 
content (9 wt%) were loaded into composite particles 
constructed of 24 kd PLGA.  Increasing the CAP-BSA 
loading reduced the proportion of PLGA in the particles 
and  diminished the amount of BSA released (Fig. 7a).  In 
contrast, raising the protein loading of polymeric particles 
prepared by water-in-oil-in-water emulsification tends to 
hasten and increase protein release [24,25].   
 
 If the CAP-BSA loading in the composite particles were 
decreased to a very low level, the complex would be 
quickly depleted by acid evolution from PLGA such that at 
later time points, even with the continual degradation of 
PLGA, there would be no further protein release.  On the 
other hand, if the proportion of CAP-BSA were increased, 
some of the complex might remain after complete PLGA 
degradation.  Plotting the percent cumulative release from 
such particles would suggest seemingly low release (Fig. 
7b).  For our experiments, we have chosen to err on the side 
of over-loading rather than under-loading apatite-protein 
complexes so that protein was continually released and 
tracked over the course of our investigation.  The complex 
loading can be adjusted so that for a precious therapeutic 
protein, a high percentage of the protein is released before 
polymer degradation is complete. 
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Fig. 7. Effect of apatite-protein complex loading on protein 
release, expressed as (a) cumulative mass of BSA released 
per mg carrier and (b) percentage cumulative release of 
BSA.  Apatite-protein loading in composite particles was 
2.0, 3.5, 10.7 and 16.7 wt%.  Particles contained 2, 3, 9 and 
15 µg of FITC-BSA per mg carrier, respectively.  
Molecular weight of PLGA used was 24 kd.     
 
IV. CONCLUSION 
 We have prepared composites of a biodegradable 
polymer (PLGA) and an inorganic substrate (apatite) as 
delivery vehicles for BSA and BMP-2.  These composites 
were formed into microparticles by a solid-in-oil-in-water 
suspension process.  The composites were capable of 
sequestering proteins, preventing their premature release.  
Controlled release was accomplished through the interplay 
of acidic product formation by polymer degradation and 
dissolution of the basic apatite.  Factors that influence 
polymer degradation and apatite dissolution include 
(b) 
(a) 
  
polymer molecular weight, polymer hydrophobicity, apatite 
particle size, and apatite loading.  We have demonstrated 
the feasibility of using these factors to modulate protein 
release profiles.  Sustained release was obtained for as short 
as 1 week to more than 3 months by varying PLGA 
molecular weight and apatite loading.  Low burst, zero-
order release was achieved for over 4 weeks through the 
use of submicron-sized apatite particles.  The rate of release 
was systematically lowered through the addition of 
buffering apatite.  This delivery platform can potentially be 
extended to other proteins.  In addition, the administration 
of a combination of therapeutic proteins may be achieved 
by loading each protein into a differently formulated 
composite to obtain a superposition of release profiles.  
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